Gliquidone

Routes of
administrationOral (tablets)ATC codeLegal statusLegal status Pharmacokinetic dataBioavailabilityHigh (T_max = 2–3 hours)MetabolismExtensive hepaticOnset of action1–1.5 hoursExcretionBiliary (95%), renal (5%)IdentifiersCAS NumberPubChem CIDDrugBankChemSpiderUNIIKEGGChEMBLCompTox Dashboard (EPA)ECHA InfoCard100.046.770 Chemical and physical dataFormulaC₂₇H₃₃N₃O₆SMolar mass527.64 g·mol⁻¹3D model (JSmol)  (verify)

Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class.^[1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).

Contraindications

• Allergy to sulfonylureas or sulfonamides
• Diabetes mellitus type 1
• Diabetic ketoacidosis
• Patients that underwent removal of the pancreas
• Acute porphyria
• Severe liver disease accompanying with liver insufficiency
• Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required
• Pregnancy or breastfeeding^[2]

Pharmacokinetics

Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.^[2]

References